Patents
Literature
61 results about "Pneumonitis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Mainly refers to inflammation of lung tissue due to non-infectious causes.
Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as PHD inhibitor compounds, compositions, and methods of use
PendingAU2024407543A1Bronchial epitheliumChronic renal disease
The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).
![Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as PHD inhibitor compounds, compositions, and methods of use](https://images-eureka.patsnap.com/patent_img/06d23532-ba88-4ae7-b1f4-6b9cf93b438e/00000568_0000.png "Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as PHD inhibitor compounds, compositions, and methods of use")
![Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as PHD inhibitor compounds, compositions, and methods of use](https://images-eureka.patsnap.com/patent_img/06d23532-ba88-4ae7-b1f4-6b9cf93b438e/00000569_0000.png "Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as PHD inhibitor compounds, compositions, and methods of use")
![Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as PHD inhibitor compounds, compositions, and methods of use](https://images-eureka.patsnap.com/patent_img/06d23532-ba88-4ae7-b1f4-6b9cf93b438e/00000570_0000.png "Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as PHD inhibitor compounds, compositions, and methods of use")
Owner:AKEBIA THERAPEUTICS INC
Random forest-based diagnostic method for pneumocystis jirovecii pneumonia
This invention proposes a random forest-based diagnostic method for Pneumocystis jirovecii pneumonia (PCP), comprising the following steps: collecting case data to form a raw dataset; cleaning and normalizing the feature encoding of the raw dataset; calculating the importance score of each feature based on three indices: permutation importance, Gini importance, and mutual information, converting it into a feature sampling probability distribution, and selecting features with sampling probabilities higher than a preset threshold; constructing a random forest model and training and optimizing it; validating the model performance using a test set and outputting the trained PCP diagnostic model; inputting standardized test samples into the diagnostic model and outputting diagnostic results. This invention solves the industry problems of intolerance to traditional invasive diagnoses, high false positive / false negative rates in routine serological tests, and insufficient generalization ability of existing machine learning models, providing non-invasive, efficient, and universal technical support for early PCP diagnosis, and is suitable for clinical application in medical institutions at all levels.
Owner:NANJING UNIV OF POSTS & TELECOMM
Endolysin with enhanced activity against biofilm pneumococci and nasopharyngeal colonization and methods thereof
PendingUS20260176309A1Polypeptide with localisation/targeting motifAntibacterial agentsDiseasePneumonitis
The present disclosure is drawn to an endolysin protein against Streptococcus pneumoniae (Spn), designated SP-CHAP. The disclosure provides methods of treating diseases in a subject resulting from infection with pneumococcal bacteria, said diseases including but not limited to pneumonia, invasive pneumococcal disease, meningitis and sepsis. Such treatment methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising SP-CHAP polypeptide, polypeptide fragments, SP-CHAP encoding nucleic acids (RNA / DNA) or variants thereof.
Owner:UNIV OF MARYLAND
Cell-based formulation containing pluripotent stem cells for diseases or post-acute sequelae caused by SARS-cov-2 infection
This cell-based formulation contains SSEA-3-positive pluripotent stem cells derived from mesenchymal tissue of a living body or derived from cultured mesenchymal cells. This cell-based formulation is characterized in that the formulation is for administration to address diseases and / or post-acute sequelae caused by SARS-CoV-2 infection. The present invention makes it possible to provide a cell-based formulation that contains pluripotent stem cells and is used for treating and / or preventing SARS-CoV-2 infection-caused diseases such as pneumonia and pulmonary fibrosis and SARS-CoV-2 infection-caused post-acute sequelae such as olfactory dysfunctions.
Owner:FUJII JUN +1
A drug delivery system for targeting treatment of inflammatory diseases and its preparation method and application
The application provides a drug delivery system for targeted treatment of inflammatory diseases and a preparation method and application thereof, and belongs to the technical field of biological drugs. The drug delivery system for targeted treatment of inflammatory diseases is M2 type macrophages phagocytizing drug-loaded nanoparticles, wherein the drug-loaded nanoparticles comprise a biodegradable high molecular material for coating drugs. The drug delivery system prepared by the application realizes lung targeted delivery through the natural inflammatory chemotaxis characteristics of M2 type macrophages, and in combination with the drug slow-release effect of the drug-loaded nanoparticles, the drug targeting and availability are significantly improved, so that the drug efficacy is improved, the biological safety is good, and a new effective means is provided for the clinical treatment of various inflammatory diseases including carbapenem-resistant Klebsiella pneumoniae (CRKP) pneumonia.
Owner:SHANGHAI DERMATOLOGY HOSPITAL +1
Method for predicting outcome of purulent lung disease caused by klebsiellapneumoniae
ActiveRU2865564C2K pneumoniaeHospitalized patients
FIELD: molecular biology.SUBSTANCE: method for predicting a high risk of adverse outcome in a patient with purulent lung disease (PLD) infected with gram-negative bacteria of the Klebsiella pneumoniae species is described. The method involves isolating DNA from peripheral venous blood and determining variants of the AQP4 rs1058424 gene. When the AQP4 rs1058424 AA genotype is detected in a patient with PLD and the presence of signs of Klebsiella pneumoniae infection, a high risk of death is determined.EFFECT: based on the determination of the AQP4 rs1058424 genotype for patients with PLD and identified gram-negative bacteria, it becomes possible to fairly early divide hospitalized patients with purulent infection into high-risk and low-risk groups for a fatal outcome.1 cl, 4 ex
Owner:FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE NAUCHNOE UCHREZHDENIE FEDERALNYJ NAUCHNO KLINICHESKIJ TSENTR REANIMATOLOGII I REABILITOLOGII FNKTS RR
A method for absolute quantification of multiple respiratory pathogens in children based on multi-target ladder microarray and exogenous internal reference correction
The application discloses a kind of absolute quantitative detection method of child respiratory tract multi-pathogen based on multi-target ladder microarray and exogenous internal reference correction.The method sets up independent micro-reaction unit to different pathogen, adds fixed amount of exogenous internal reference nucleic acid, and calculates template number by positive unit proportion combined with Poisson distribution model, then corrects the result by using the theoretical addition amount of exogenous internal reference, so as to realize parallel detection and absolute quantification of pathogen such as bocavirus, adenovirus, mycobacterium tuberculosis and mycoplasma pneumoniae without standard curve and special digital PCR equipment.The application has the advantages of high sensitivity, strong anti-interference ability, suitable for mixed infection sample analysis and clinical application, etc.
Owner:NANJING MEDICAL UNIV
Pharmaceutical composition for inhibiting inflammation and use thereof
This invention provides pharmaceutical compositions for inhibiting inflammation and their applications. The invention reveals that the combined use of hyaluronic acid synthesis inhibitors and ascorbate palmitate or their analogues can synergistically inhibit inflammation, significantly improving the therapeutic effect; the inflammation may include systemic inflammation and SARS-CoV-2 infection-related inflammation, including pneumonia. This invention also reveals a novel coronavirus inflammation model obtained by stimulating cells with specially isolated polynucleotides derived from the novel coronavirus genome. The model exhibits a typical inflammatory phenotype, is stable and controllable, and is intuitive and easy to observe.
Owner:SHANGHAI YIZHE BIOTECHNOLOGY CO LTD
Respiratory aqueous solution composition containing molecular iodine
The present invention provides an aqueous solution composition capable of rapidly preventing, alleviating or eliminating symptoms of acute respiratory diseases by applying a hypertonic aqueous solution composition containing molecular iodine to all parts of the eyes, oral cavity, nasal cavity, and respiratory tract. The present invention provides a hypertonic aqueous solution composition containing molecular iodine, which can prevent and eliminate acute respiratory infectious diseases such as cold, flu, and COVID-19, and can rapidly alleviate or eliminate runny nose and nasal congestion caused by allergic and non-allergic rhinitis.
Owner:KIM DAE WHANG
Method and device for constructing a risk prediction model for TKI pneumonitis
The application relates to a TKI pneumonia risk prediction model construction method and device, computer equipment and a storage medium. The method comprises the following steps: acquiring a preset number of historical risk prediction feature data sets; the historical risk prediction feature data sets comprise historical imageomics feature data, historical deep learning feature data, historical visual bag-of-words feature data and historical clinical feature data; each risk prediction feature data set is randomly divided to generate a training sample set and a test sample set; an initial TKI pneumonia risk prediction model is trained according to the training sample set, and the initial TKI pneumonia risk prediction model is tested according to the test sample set; the model parameters of the initial TKI pneumonia risk prediction model are adjusted based on the indexes obtained by training and testing, until the indexes meet preset requirements, and a trained TKI pneumonia risk prediction model is generated. The method can improve the reliability and accuracy of TKI pneumonia risk prediction.
Owner:GUANGDONG GENERAL HOSPITAL
Use of BCG immunogenic formulation expressing a respiratory syncitial virus protein against hMPV
ActiveUS12667611B2BCG immunizationVirus Protein
The invention relates to the novel use of an immunogenic formulation containing the bacillus Calmette-Guérin (BCG) strain at a concentration between 10-10° bacteria, expressing at least one protein or immunogenic fragment of respiratory syncytial virus (RSV, Human Orthopneumovirus), in a pharmaceutically acceptable saline buffer solution because it serves to prepare a vaccine useful to prevent, treat, or attenuate human Metapneumovirus (hMPV) infections.
Owner:PONTIFISIA UNIVERSIDAD KATOLIKA DE CHILE
Use of a traditional Chinese medicine composition in the preparation of a medicine for viral pneumonia
ActiveCN118384213BReduce lung index in mixed-infected miceIncreased lung index in infected miceAntibacterial agentsAntiviralsPharmaceutical drugSaposhnikovia
The application relates to an application of a traditional Chinese medicine composition in a drug for viral pneumonia, which comprises 10-15 parts of wind-preventing, 10-15 parts of perilla leaf, 2-6 parts of Ephedra, 7-9 parts of Schisandra chinensis, 7-9 parts of white ginkgo, 7-9 parts of bitter almond, 7-9 parts of purple aster, 7-9 parts of dogwood fruit and 7-9 parts of lily of the valley. The traditional Chinese medicine composition can obviously inhibit the increase of the lung index of respiratory syncytial virus (RSV) infected mice and has a better treatment effect on viral pneumonia.
Owner:JIANGSU KANION PHARMA CO LTD
An antibody-antibiotic conjugate and uses thereof
The application discloses an antibody-antibiotic conjugate and application thereof, and a structural formula of the antibody-antibiotic conjugate is shown as formula (I) and is composed of a payload antibiotic, a monoclonal antibody targeting Kdo monosaccharide and an enzyme-sensitive linker; the antibody-antibiotic conjugate has strong affinity to Kdo antigen and can be combined with Staphylococcus aureus of different serotypes. Enzymatic treatment of the antibody-antibiotic conjugate can release free antibiotics to improve the bactericidal efficiency on Staphylococcus aureus; the antibody-antibiotic conjugate can effectively kill intracellular bacteria which are difficult to be affected by traditional small-molecule antibiotics through the mediation of the antibody; in the application of a Staphylococcus aureus-induced mouse pneumonia and nephritis model, the antibody-antibiotic conjugate can effectively remove bacteria in the lung and kidney, and the therapeutic effect is better than that of vancomycin. Therefore, the antibody-antibiotic conjugate has potential application in the development of Staphylococcus aureus infection drugs.
Owner:EAST CHINA UNIV OF SCI & TECH +1
Immunobiotics for preventing bacterial pneumonia and methods of using the same
Methods for treating or preventing bacterial pneumonia in a subject involve administration of a Prevotella composition to the subject. The Prevotella composition may include cells, or portions thereof, of one or more of P. melaninogenica, P. buccae, P. tannerae, and P. nanceiensis. The composition may be administered by inhalation.
Owner:THE REGENTS OF THE UNIVERSITY OF COLORADO
A way to alleviate PM 2.5 Platycodon grandiflorum polysaccharides that cause respiratory diseases and their applications
Owner:TIANJIN UNIV OF SCI & TECH
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits and uses thereof
Owner:PFIZER INC
A mycoplasma pneumoniae three-component recombinant subunit vaccine composition and use thereof
This invention relates to the field of biomedical technology, specifically disclosing a three-component recombinant subunit vaccine composition for Mycoplasma pneumoniae and its application. The vaccine composition comprises key antigenic proteins of Mycoplasma pneumoniae (MP): P1 protein, P40 / 90 protein, and an E132A attenuated mutant of community-acquired respiratory distress syndrome (CARDS) toxin (CARDS-Mut), optionally combined with Al(OH)3 single adjuvant or Al(OH)3+CPG double adjuvant. The recombinant protein was successfully purified using a prokaryotic expression system, and validated in a mouse model. The vaccine induces high-titer specific IgG antibodies, significantly alleviates lung tissue pathological damage, reduces bacterial load, and inhibits inflammatory factor secretion after challenge, with good safety. This invention solves the problem of high toxicity of CARDS toxin, providing an efficient and safe vaccine strategy for the prevention and control of MP infection.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES
A mycoplasma hyopneumoniae antigen, protein nanoparticle, vaccine, and methods of making and use
The application provides a Mycoplasma hyopneumoniae antigen, a protein nanoparticle, a vaccine and a preparation method and application; the Mycoplasma hyopneumoniae antigen comprises SpyCatcher fusion proteins of ENOLASE, EF-TU, FBA, GAPDH, NOX, NFOR, MHP107, MHP597, MHP683, MHJ0461, MNUA, P28, P36, P42, P46, P65, P94, P97, P102, P110, P116, P146, P159, P216; and the protein nanoparticle of the Mycoplasma hyopneumoniae antigen is formed by self-assembly of the Mycoplasma hyopneumoniae antigen and an AP205-Spytag nanoparticle. The application provides 24 kinds of fusion proteins as Mycoplasma hyopneumoniae antigens, realizes connection of the fusion proteins and the nanoparticle, and further obtains a vaccine component for efficiently immunizing pigs against Mycoplasma hyopneumoniae.
Owner:湖南派智生物科技有限公司
Algae-based microrobot for drug delivery
Microalgae combined with antibiotic-loaded neutrophil membrane-coated polymeric nanoparticles provide a hybrid microrobot having robust locomotion in the lungs in vivo toward effective treatment of pulmonary and gastrointestinal tract infections. The algae-nanoparticle hybrid microrobots are provided in methods of treatment of disease or conditions by administration for active in vivo delivery of therapeutics to the lungs or gastrointestinal tract. The microrobot system can be applied to treat a wide range of diseases, including viral pneumonia.
Owner:RGT UNIV OF CALIFORNIA
Immunogenic composition containing non-natural amino acids for the prevention and treatment of pneumococcal infections
PCT designated stageWO2026136167A1Bacterial antigen ingredientsAntibacterial agentsT cellImmunity response
This invention relates to immunogenic compositions for the prevention and treatment of infection due to Streptococcus pneumoniae containing P4 peptide and / or detoxified pneumolysin protein conjugated to a T cell stimulating epitope as a contiguous peptide sequence. In particular, non-natural amino acid sequences inserted between the structures create points of conjugation that do not interfere with the generation of an effective immune response. This invention is also directed to method for the manufacture of these compositions and administration of these compositions to subjects.
Owner:INVENTPRISE INC
Radiation pneumonia risk prediction method and system based on federal transfer learning
Owner:ZHEJIANG CANCER HOSPITAL
Artificial intelligence-based rapid assessment method and system for ultrasound images of pneumonia
ActiveCN114767153BLeft ventricular sizeTele operation
The present application relates to the technical field of biology, and discloses a method for rapidly evaluating pneumonia, especially COVID-19, based on artificial intelligence, which comprises the following steps: 1) obtaining lung region ultrasound images and circulatory volume ultrasound images of a subject, wherein the circulatory volume ultrasound images comprise left ventricular outflow tract ultrasound images, left ventricular long-axis section ultrasound images and inferior vena cava long-axis section ultrasound images; 2) inputting the lung region ultrasound images and the circulatory volume ultrasound images of the subject into a trained deep convolutional neural network model, wherein the trained deep convolutional neural network model comprises a trained lung ultrasound image scoring model and a trained circulatory volume ultrasound image scoring model, so as to obtain the evaluation result of pneumonia of the subject. The present application also discloses a trained deep convolutional neural network model suitable for pneumonia, especially COVID-19, a construction method of the trained deep convolutional neural network model, and a remote operation ultrasound robot comprising the trained deep convolutional neural network model.
Owner:IMABOT SHENZHEN MEDICAL CO LTD
Use of bacterial compositions in the treatment and prophylaxis of airway diseases
The present invention relates to the use of bacterial compositions having an arginine deiminase activity (inhibition of nitric oxide synthase by conversion of L-arginine to L-citrulline) of 1-1,000 μmol L-citrulline / h / g composition and a sphingomyelinase (ceramide generation) activity of 0.01-1.000 nmoles ceramides / h / g composition in the treatment and / or prophylaxis of airway diseases caused by viruses such as influenza viruses, coronaviruses, as SARS-CoV, MERS-CoV and SARS-CoV-2, avian viruses, respiratory syncytial virus (VRS), rhinoviruses, pneumoviruses, or respiratory failure induced or aggravated by viral infections, angina pectoris, pulmonary heart, respiratory distress, pulmonary edema, neonatal asphyxia, myocardial infarction, heart failure, respiratory failure Pickwick syndrome, pulmonary hypertension, pneumonia or even cystic fibrosis (CF) aggravated by viral infections.
Owner:DE SIMONE CLAUDIO
Application of reagent for targeted inhibition of ADAM10 in treatment or prevention of inflammation caused by virus infection
The invention belongs to the field of biological medicine, and particularly relates to application of an ADAM10-targeted inhibitor to treatment or prevention of inflammation caused by virus infection. Specifically, abnormal fusion between immune cells (such as mononuclear cells and macrophages) and infected pulmonary epithelial cells in the virus infection process and excessive activation caused by the abnormal fusion can be specifically blocked by inhibiting activity or expression of ADAM10, so that generation of proinflammatory cytokines (such as IL-6, IL-1beta and TNF-alpha) is effectively reduced. The methods are particularly useful in the treatment or prevention of inflammatory responses induced by viral infections and related inflammatory diseases, such as viral pneumonia and acute respiratory distress syndrome. Compared with a broad-spectrum immunosuppressor, the invention provides a novel anti-inflammatory treatment strategy with stronger targeting property and smaller potential side effect.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Use of a traditional Chinese medicine composition in treating radiation pneumonia
PendingCN122321067ACMV PneumoniaLung Inflammations
This invention belongs to the field of traditional Chinese medicine application technology and provides an application of a traditional Chinese medicine composition in the treatment of radiation-induced pneumonia. The traditional Chinese medicine composition is made from bamboo sap and *Trifolium repens*; the mass ratio of bamboo sap to *Trifolium repens* is (1-10):(1-10). Radiation-induced pneumonia refers to lung inflammation caused by radiotherapy for malignant tumors of the chest. The traditional Chinese medicine composition provided by this invention has the effects of clearing heat and detoxifying, resolving phlegm and dissipating nodules. It has a simple composition and high safety, providing a new option for the treatment of radiation-induced pneumonia.
Owner:JINAN SUNNYPHARMACY